Clinical Trial

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Protocol Amendment History 3 changes
notable Trial sites expanded: 12 -> 22 locations 2026-06-27
critical Recruitment opened 2026-05-19
notable Trial sites expanded: 0 -> 12 locations 2026-05-19
Trial Details
NCT Number NCT07489651
Lead Sponsor Reunion Neuroscience Inc
Conditions Generalized Anxiety Disorder
Enrollment 64 participants
Start Date 2026-04-20
Primary Completion 2027-02 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-26